Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease

First Dept. of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. BACKGROUND AND OBJECTIVES: Pure infradiaphragmatic Hodgkin's lymphoma (HL) is a rare disease. The prognostic impact of a purely infradiaphragmatic localization of this lymp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haematologica (Roma) 2006-01, Vol.91 (1), p.32-39
Hauptverfasser: Vassilakopoulos, TP, Angelopoulou, MK, Siakantaris, MP, Konstantinou, N, Symeonidis, A, Karmiris, T, Repoussis, P, Roussou, P, Dimopoulos, AM, Kokoris, SI, Dimitriadou, EM, Kyrtsonis, MC, Dimopoulou, MN, Tsatalas, C, Kokkinis, G, Vrakidou, E, Grigoraki, V, Poziopoulos, C, Stamatellou, M, Liapis, D, Georgiou, G, Panayiotidis, P, Pangalis, GA, Hellenic Cooperative Lymphoma Group
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 39
container_issue 1
container_start_page 32
container_title Haematologica (Roma)
container_volume 91
creator Vassilakopoulos, TP
Angelopoulou, MK
Siakantaris, MP
Konstantinou, N
Symeonidis, A
Karmiris, T
Repoussis, P
Roussou, P
Dimopoulos, AM
Kokoris, SI
Dimitriadou, EM
Kyrtsonis, MC
Dimopoulou, MN
Tsatalas, C
Kokkinis, G
Vrakidou, E
Grigoraki, V
Poziopoulos, C
Stamatellou, M
Liapis, D
Georgiou, G
Panayiotidis, P
Pangalis, GA
Hellenic Cooperative Lymphoma Group
description First Dept. of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. BACKGROUND AND OBJECTIVES: Pure infradiaphragmatic Hodgkin's lymphoma (HL) is a rare disease. The prognostic impact of a purely infradiaphragmatic localization of this lymphoma is controversial. We aimed to evaluate the baseline clinicopathologic features, prognostic factors and outcome of a large series of consecutive patients with pure infradiaphragmatic HL. DESIGN AND METHODS: We analyzed 131 patients with clinical stage I/II infradiaphragmatic HL treated with ABVD or equivalent regimens with or without radiotherapy, and compared 54 of them with 444 patients with pure supradiaphragmatic disease, who were treated at the same center. RESULTS: Older age, clinical stage II (borderline), involvement of > or =3 sites, lymphocyte predominant histology, elevated serum beta2-microglobulin and higher International Prognostic Score were more frequent in patients with infradiaphragmatic disease than in those with supradiaphragmatic disease, while nodular sclerosis was less frequent. The complete remission rate was 100%, 97% and 82% for stages I, IIA and IIB, respectively. Only B-symptoms independently predicted for inferior failure-free survival, while inferior overall survival was independently associated with the involvement of > or =3 sites. At 10 years failure-free survival was 82+/-6% (vs. 85+/-2% for patients with supradiaphragmatic disease, p=0.45), overall survival was 74+/-8% (vs. 91+/-2%, p=0.0006), and disease-specific survival 87+/-5% (vs. 94+/-1%, p=0.04). In multivariate analysis the differences between infradiaphragmatic and supradiaphragmatic disease were obscured by older age and B-symptoms. INTERPRETATION AND CONCLUSIONS: Pure infradiaphragmatic HL presents with distinct clinicopathologic characteristics. The previously reported poorer outcome may be explained by the unfavorable profile of the patients rather than the infradiaphragmatic presentation per se. Patients with stage IIB disease should probably be classified as having advanced HL because of the unacceptable rate of primary refractory disease.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70710191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70710191</sourcerecordid><originalsourceid>FETCH-LOGICAL-h838-45edbdaf7715f394c59f7d1d85b2cf393d4090ff6a254852a3ab6c9c4539d4673</originalsourceid><addsrcrecordid>eNpd0MtKw0AUBuAgiq3VV5BZiG6MzC2ZzFKKWqGgi-7DyVyS0dycSQhd-epGWjeuDhy-_-dwTqIlSSSNM0HJabTETOI4xSJbRBchfGBMsZTiPFqQlDPO0mwZfb-P3iDXWg_aQV95KBsYnEKbTpefrr0LqN43fdU18IDWtWudghpZA8OcC_eo913ZduE3YUENnUfQaqS6pgfvQteiyQ0VCmP_v1-7YCCYy-jMQh3M1XGuot3z0269ibdvL6_rx21cZSyLeWJ0ocEKQRLLJFeJtEITnSUFVfOCaY4ltjYFmvAsocCgSJVUPGFS81SwVXR7qJ3v_RpNGPLGBWXqGlrTjSEXWBBMJJnh9RGORWN03nvXgN_nfx-bwc0BVK6sJudNHhqo65nTfJomSXKSM8p-AOKAeF4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70710191</pqid></control><display><type>article</type><title>Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Vassilakopoulos, TP ; Angelopoulou, MK ; Siakantaris, MP ; Konstantinou, N ; Symeonidis, A ; Karmiris, T ; Repoussis, P ; Roussou, P ; Dimopoulos, AM ; Kokoris, SI ; Dimitriadou, EM ; Kyrtsonis, MC ; Dimopoulou, MN ; Tsatalas, C ; Kokkinis, G ; Vrakidou, E ; Grigoraki, V ; Poziopoulos, C ; Stamatellou, M ; Liapis, D ; Georgiou, G ; Panayiotidis, P ; Pangalis, GA ; Hellenic Cooperative Lymphoma Group</creator><creatorcontrib>Vassilakopoulos, TP ; Angelopoulou, MK ; Siakantaris, MP ; Konstantinou, N ; Symeonidis, A ; Karmiris, T ; Repoussis, P ; Roussou, P ; Dimopoulos, AM ; Kokoris, SI ; Dimitriadou, EM ; Kyrtsonis, MC ; Dimopoulou, MN ; Tsatalas, C ; Kokkinis, G ; Vrakidou, E ; Grigoraki, V ; Poziopoulos, C ; Stamatellou, M ; Liapis, D ; Georgiou, G ; Panayiotidis, P ; Pangalis, GA ; Hellenic Cooperative Lymphoma Group ; Hellenic Cooperative Lymphoma Group</creatorcontrib><description>First Dept. of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. BACKGROUND AND OBJECTIVES: Pure infradiaphragmatic Hodgkin's lymphoma (HL) is a rare disease. The prognostic impact of a purely infradiaphragmatic localization of this lymphoma is controversial. We aimed to evaluate the baseline clinicopathologic features, prognostic factors and outcome of a large series of consecutive patients with pure infradiaphragmatic HL. DESIGN AND METHODS: We analyzed 131 patients with clinical stage I/II infradiaphragmatic HL treated with ABVD or equivalent regimens with or without radiotherapy, and compared 54 of them with 444 patients with pure supradiaphragmatic disease, who were treated at the same center. RESULTS: Older age, clinical stage II (borderline), involvement of &gt; or =3 sites, lymphocyte predominant histology, elevated serum beta2-microglobulin and higher International Prognostic Score were more frequent in patients with infradiaphragmatic disease than in those with supradiaphragmatic disease, while nodular sclerosis was less frequent. The complete remission rate was 100%, 97% and 82% for stages I, IIA and IIB, respectively. Only B-symptoms independently predicted for inferior failure-free survival, while inferior overall survival was independently associated with the involvement of &gt; or =3 sites. At 10 years failure-free survival was 82+/-6% (vs. 85+/-2% for patients with supradiaphragmatic disease, p=0.45), overall survival was 74+/-8% (vs. 91+/-2%, p=0.0006), and disease-specific survival 87+/-5% (vs. 94+/-1%, p=0.04). In multivariate analysis the differences between infradiaphragmatic and supradiaphragmatic disease were obscured by older age and B-symptoms. INTERPRETATION AND CONCLUSIONS: Pure infradiaphragmatic HL presents with distinct clinicopathologic characteristics. The previously reported poorer outcome may be explained by the unfavorable profile of the patients rather than the infradiaphragmatic presentation per se. Patients with stage IIB disease should probably be classified as having advanced HL because of the unacceptable rate of primary refractory disease.</description><identifier>ISSN: 0390-6078</identifier><identifier>EISSN: 1592-8721</identifier><identifier>PMID: 16434368</identifier><language>eng</language><publisher>Italy</publisher><subject>Hodgkin Disease - drug therapy ; Hodgkin Disease - radiotherapy ; Hodgkin Disease - therapy ; Humans ; Prognosis ; Remission Induction ; Survival Analysis ; Treatment Outcome</subject><ispartof>Haematologica (Roma), 2006-01, Vol.91 (1), p.32-39</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16434368$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vassilakopoulos, TP</creatorcontrib><creatorcontrib>Angelopoulou, MK</creatorcontrib><creatorcontrib>Siakantaris, MP</creatorcontrib><creatorcontrib>Konstantinou, N</creatorcontrib><creatorcontrib>Symeonidis, A</creatorcontrib><creatorcontrib>Karmiris, T</creatorcontrib><creatorcontrib>Repoussis, P</creatorcontrib><creatorcontrib>Roussou, P</creatorcontrib><creatorcontrib>Dimopoulos, AM</creatorcontrib><creatorcontrib>Kokoris, SI</creatorcontrib><creatorcontrib>Dimitriadou, EM</creatorcontrib><creatorcontrib>Kyrtsonis, MC</creatorcontrib><creatorcontrib>Dimopoulou, MN</creatorcontrib><creatorcontrib>Tsatalas, C</creatorcontrib><creatorcontrib>Kokkinis, G</creatorcontrib><creatorcontrib>Vrakidou, E</creatorcontrib><creatorcontrib>Grigoraki, V</creatorcontrib><creatorcontrib>Poziopoulos, C</creatorcontrib><creatorcontrib>Stamatellou, M</creatorcontrib><creatorcontrib>Liapis, D</creatorcontrib><creatorcontrib>Georgiou, G</creatorcontrib><creatorcontrib>Panayiotidis, P</creatorcontrib><creatorcontrib>Pangalis, GA</creatorcontrib><creatorcontrib>Hellenic Cooperative Lymphoma Group</creatorcontrib><creatorcontrib>Hellenic Cooperative Lymphoma Group</creatorcontrib><title>Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>First Dept. of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. BACKGROUND AND OBJECTIVES: Pure infradiaphragmatic Hodgkin's lymphoma (HL) is a rare disease. The prognostic impact of a purely infradiaphragmatic localization of this lymphoma is controversial. We aimed to evaluate the baseline clinicopathologic features, prognostic factors and outcome of a large series of consecutive patients with pure infradiaphragmatic HL. DESIGN AND METHODS: We analyzed 131 patients with clinical stage I/II infradiaphragmatic HL treated with ABVD or equivalent regimens with or without radiotherapy, and compared 54 of them with 444 patients with pure supradiaphragmatic disease, who were treated at the same center. RESULTS: Older age, clinical stage II (borderline), involvement of &gt; or =3 sites, lymphocyte predominant histology, elevated serum beta2-microglobulin and higher International Prognostic Score were more frequent in patients with infradiaphragmatic disease than in those with supradiaphragmatic disease, while nodular sclerosis was less frequent. The complete remission rate was 100%, 97% and 82% for stages I, IIA and IIB, respectively. Only B-symptoms independently predicted for inferior failure-free survival, while inferior overall survival was independently associated with the involvement of &gt; or =3 sites. At 10 years failure-free survival was 82+/-6% (vs. 85+/-2% for patients with supradiaphragmatic disease, p=0.45), overall survival was 74+/-8% (vs. 91+/-2%, p=0.0006), and disease-specific survival 87+/-5% (vs. 94+/-1%, p=0.04). In multivariate analysis the differences between infradiaphragmatic and supradiaphragmatic disease were obscured by older age and B-symptoms. INTERPRETATION AND CONCLUSIONS: Pure infradiaphragmatic HL presents with distinct clinicopathologic characteristics. The previously reported poorer outcome may be explained by the unfavorable profile of the patients rather than the infradiaphragmatic presentation per se. Patients with stage IIB disease should probably be classified as having advanced HL because of the unacceptable rate of primary refractory disease.</description><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - radiotherapy</subject><subject>Hodgkin Disease - therapy</subject><subject>Humans</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0390-6078</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0MtKw0AUBuAgiq3VV5BZiG6MzC2ZzFKKWqGgi-7DyVyS0dycSQhd-epGWjeuDhy-_-dwTqIlSSSNM0HJabTETOI4xSJbRBchfGBMsZTiPFqQlDPO0mwZfb-P3iDXWg_aQV95KBsYnEKbTpefrr0LqN43fdU18IDWtWudghpZA8OcC_eo913ZduE3YUENnUfQaqS6pgfvQteiyQ0VCmP_v1-7YCCYy-jMQh3M1XGuot3z0269ibdvL6_rx21cZSyLeWJ0ocEKQRLLJFeJtEITnSUFVfOCaY4ltjYFmvAsocCgSJVUPGFS81SwVXR7qJ3v_RpNGPLGBWXqGlrTjSEXWBBMJJnh9RGORWN03nvXgN_nfx-bwc0BVK6sJudNHhqo65nTfJomSXKSM8p-AOKAeF4</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>Vassilakopoulos, TP</creator><creator>Angelopoulou, MK</creator><creator>Siakantaris, MP</creator><creator>Konstantinou, N</creator><creator>Symeonidis, A</creator><creator>Karmiris, T</creator><creator>Repoussis, P</creator><creator>Roussou, P</creator><creator>Dimopoulos, AM</creator><creator>Kokoris, SI</creator><creator>Dimitriadou, EM</creator><creator>Kyrtsonis, MC</creator><creator>Dimopoulou, MN</creator><creator>Tsatalas, C</creator><creator>Kokkinis, G</creator><creator>Vrakidou, E</creator><creator>Grigoraki, V</creator><creator>Poziopoulos, C</creator><creator>Stamatellou, M</creator><creator>Liapis, D</creator><creator>Georgiou, G</creator><creator>Panayiotidis, P</creator><creator>Pangalis, GA</creator><creator>Hellenic Cooperative Lymphoma Group</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease</title><author>Vassilakopoulos, TP ; Angelopoulou, MK ; Siakantaris, MP ; Konstantinou, N ; Symeonidis, A ; Karmiris, T ; Repoussis, P ; Roussou, P ; Dimopoulos, AM ; Kokoris, SI ; Dimitriadou, EM ; Kyrtsonis, MC ; Dimopoulou, MN ; Tsatalas, C ; Kokkinis, G ; Vrakidou, E ; Grigoraki, V ; Poziopoulos, C ; Stamatellou, M ; Liapis, D ; Georgiou, G ; Panayiotidis, P ; Pangalis, GA ; Hellenic Cooperative Lymphoma Group</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h838-45edbdaf7715f394c59f7d1d85b2cf393d4090ff6a254852a3ab6c9c4539d4673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - radiotherapy</topic><topic>Hodgkin Disease - therapy</topic><topic>Humans</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vassilakopoulos, TP</creatorcontrib><creatorcontrib>Angelopoulou, MK</creatorcontrib><creatorcontrib>Siakantaris, MP</creatorcontrib><creatorcontrib>Konstantinou, N</creatorcontrib><creatorcontrib>Symeonidis, A</creatorcontrib><creatorcontrib>Karmiris, T</creatorcontrib><creatorcontrib>Repoussis, P</creatorcontrib><creatorcontrib>Roussou, P</creatorcontrib><creatorcontrib>Dimopoulos, AM</creatorcontrib><creatorcontrib>Kokoris, SI</creatorcontrib><creatorcontrib>Dimitriadou, EM</creatorcontrib><creatorcontrib>Kyrtsonis, MC</creatorcontrib><creatorcontrib>Dimopoulou, MN</creatorcontrib><creatorcontrib>Tsatalas, C</creatorcontrib><creatorcontrib>Kokkinis, G</creatorcontrib><creatorcontrib>Vrakidou, E</creatorcontrib><creatorcontrib>Grigoraki, V</creatorcontrib><creatorcontrib>Poziopoulos, C</creatorcontrib><creatorcontrib>Stamatellou, M</creatorcontrib><creatorcontrib>Liapis, D</creatorcontrib><creatorcontrib>Georgiou, G</creatorcontrib><creatorcontrib>Panayiotidis, P</creatorcontrib><creatorcontrib>Pangalis, GA</creatorcontrib><creatorcontrib>Hellenic Cooperative Lymphoma Group</creatorcontrib><creatorcontrib>Hellenic Cooperative Lymphoma Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vassilakopoulos, TP</au><au>Angelopoulou, MK</au><au>Siakantaris, MP</au><au>Konstantinou, N</au><au>Symeonidis, A</au><au>Karmiris, T</au><au>Repoussis, P</au><au>Roussou, P</au><au>Dimopoulos, AM</au><au>Kokoris, SI</au><au>Dimitriadou, EM</au><au>Kyrtsonis, MC</au><au>Dimopoulou, MN</au><au>Tsatalas, C</au><au>Kokkinis, G</au><au>Vrakidou, E</au><au>Grigoraki, V</au><au>Poziopoulos, C</au><au>Stamatellou, M</au><au>Liapis, D</au><au>Georgiou, G</au><au>Panayiotidis, P</au><au>Pangalis, GA</au><au>Hellenic Cooperative Lymphoma Group</au><aucorp>Hellenic Cooperative Lymphoma Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>91</volume><issue>1</issue><spage>32</spage><epage>39</epage><pages>32-39</pages><issn>0390-6078</issn><eissn>1592-8721</eissn><abstract>First Dept. of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. BACKGROUND AND OBJECTIVES: Pure infradiaphragmatic Hodgkin's lymphoma (HL) is a rare disease. The prognostic impact of a purely infradiaphragmatic localization of this lymphoma is controversial. We aimed to evaluate the baseline clinicopathologic features, prognostic factors and outcome of a large series of consecutive patients with pure infradiaphragmatic HL. DESIGN AND METHODS: We analyzed 131 patients with clinical stage I/II infradiaphragmatic HL treated with ABVD or equivalent regimens with or without radiotherapy, and compared 54 of them with 444 patients with pure supradiaphragmatic disease, who were treated at the same center. RESULTS: Older age, clinical stage II (borderline), involvement of &gt; or =3 sites, lymphocyte predominant histology, elevated serum beta2-microglobulin and higher International Prognostic Score were more frequent in patients with infradiaphragmatic disease than in those with supradiaphragmatic disease, while nodular sclerosis was less frequent. The complete remission rate was 100%, 97% and 82% for stages I, IIA and IIB, respectively. Only B-symptoms independently predicted for inferior failure-free survival, while inferior overall survival was independently associated with the involvement of &gt; or =3 sites. At 10 years failure-free survival was 82+/-6% (vs. 85+/-2% for patients with supradiaphragmatic disease, p=0.45), overall survival was 74+/-8% (vs. 91+/-2%, p=0.0006), and disease-specific survival 87+/-5% (vs. 94+/-1%, p=0.04). In multivariate analysis the differences between infradiaphragmatic and supradiaphragmatic disease were obscured by older age and B-symptoms. INTERPRETATION AND CONCLUSIONS: Pure infradiaphragmatic HL presents with distinct clinicopathologic characteristics. The previously reported poorer outcome may be explained by the unfavorable profile of the patients rather than the infradiaphragmatic presentation per se. Patients with stage IIB disease should probably be classified as having advanced HL because of the unacceptable rate of primary refractory disease.</abstract><cop>Italy</cop><pmid>16434368</pmid><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0390-6078
ispartof Haematologica (Roma), 2006-01, Vol.91 (1), p.32-39
issn 0390-6078
1592-8721
language eng
recordid cdi_proquest_miscellaneous_70710191
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals
subjects Hodgkin Disease - drug therapy
Hodgkin Disease - radiotherapy
Hodgkin Disease - therapy
Humans
Prognosis
Remission Induction
Survival Analysis
Treatment Outcome
title Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T07%3A08%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pure%20infradiaphragmatic%20Hodgkin's%20lymphoma.%20Clinical%20features,%20prognostic%20factor%20and%20comparison%20with%20supradiaphragmatic%20disease&rft.jtitle=Haematologica%20(Roma)&rft.au=Vassilakopoulos,%20TP&rft.aucorp=Hellenic%20Cooperative%20Lymphoma%20Group&rft.date=2006-01-01&rft.volume=91&rft.issue=1&rft.spage=32&rft.epage=39&rft.pages=32-39&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70710191%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70710191&rft_id=info:pmid/16434368&rfr_iscdi=true